<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131237">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02032277</url>
  </required_header>
  <id_info>
    <org_study_id>M14-011</org_study_id>
    <secondary_id>2013-002377-21</secondary_id>
    <nct_id>NCT02032277</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer</brief_title>
  <acronym>Brightness</acronym>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Oncology Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Surgical Adjuvant Breast and Bowel Project (NSABP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Espanol de Investigacion del Cancer de Mama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of
      veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant
      chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR).</measure>
    <time_frame>At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pathological complete response (pCR) in the breast tissue and the lymph node tissue will be assessed upon completion of pre-operative systemic therapy and definitive surgery.  Subjects who do not complete definitive surgery for reasons other than withdrawal of consent will be considered not to have achieved pCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of eligibility for breast conservation after therapy (BCR).</measure>
    <time_frame>At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether a subject is eligible for breast conserving surgery will be determined by the subject's surgeon prior to chemotherapy and after completion of chemotherapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Up to 10 years from first dose of study drug.</time_frame>
    <safety_issue>No</safety_issue>
    <description>EFS will be defined as the time from random assignment to documentation of the first of the following events:  failure to reach potential curative surgery; local, regional, or distant invasive recurrence of breast cancer following curative surgery; a contralateral breast cancer; a new onset malignancy; or death as a result of any cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 10 years from first dose of study drug.</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be defined as the number of days from the day the subject is randomized to the date of the subject's death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Response Rate (CRR)</measure>
    <time_frame>First day of treatment on Chemotherapy Segment 2 (approximately 12-16 weeks from first dose of study drug).</time_frame>
    <safety_issue>No</safety_issue>
    <description>CRR at 12 weeks and tumor sizes at 12 weeks will be summarized at the end of the Chemotherapy Segment 1 of the treatment (reported at visit AC1) to assess the objective response rate. CRR is defined as the proportion of subjects with complete or partial response of the primary tumor as determined by the central imaging vendor.</description>
  </other_outcome>
  <other_outcome>
    <measure>pCR plus minimal residual disease (defined as residual cancer burden [RCB] class I)</measure>
    <time_frame>At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug).</time_frame>
    <safety_issue>No</safety_issue>
    <description>RCB in the breast tissue and the lymph node tissue will be assessed upon completion of pre-operative systemic therapy and definitive surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status.</measure>
    <time_frame>First day of treatment (Day 1) to Pre-Op Visit (approximately 22-32 weeks from first dose of study drug).</time_frame>
    <safety_issue>No</safety_issue>
    <description>ECOG performance status will be determined by the Investigator at each assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Breast cancer related quality of life (QoL).</measure>
    <time_frame>First day of treatment (Day 1) up to 6 months during the post-surgery follow-up period (approximately 15 months from first dose of study drug).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Breast cancer related QoL will be assessed via the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), Breast Cancer module (EORTC QLQ-BR23) and European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaires.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">624</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + carboplatin + paclitaxel followed by AC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + placebo + paclitaxel followed by AC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Veliparib</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed invasive breast cancer by core needle or incisional biopsy
             (excisional biopsy is not allowed).  Clinical stage T2-4 N0-2 or T1 N1-2 by physical
             exam or radiologic studies.

          2. Documented Breast Cancer Gene (BRCA) germline mutation testing.

          3. Estrogen Receptor (ER)-, Progesterone Receptor (PR)-, and Human Epidermal Growth
             Factor Receptor (HER)2-negative (triple-negative) cancer of the breast.

          4. ECOG Performance status of 0 to 1.

          5. Women must be determined to be not of childbearing potential (surgically sterile, or
             postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR
             they must have a negative serum pregnancy test prior to randomization.

        Exclusion Criteria:

          1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic
             therapy radiotherapy or investigational agents) with therapeutic intent for current
             breast cancer.

          2. Previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a
             Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.

          3. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal
             agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator
             (SERM).  Subjects must have discontinued use of such agents prior to beginning study
             treatment.

          4. A history of seizure within 12 months prior to study entry.

          5. Pre-existing neuropathy from any cause in excess of Grade 1.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark  McKee, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian  Oliver, BS</last_name>
    <phone>847-938-5570</phone>
    <email>brian.oliver@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliannn  Dziubinski, BS</last_name>
    <phone>847-937-5838</phone>
    <email>juliann.dziubinski@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118035</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118035</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118215</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118215</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116815</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 116815</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118775</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118775</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 119179</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 119179</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118677</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 118677</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Austrian Breast &amp; Colorectal Cancer Study Group - ABCSG 44</keyword>
  <keyword>National Surgical Adjuvant Breast and Bowel Project - B-56-I</keyword>
  <keyword>United States Oncology - 12152</keyword>
  <keyword>Alliance - AFT-04</keyword>
  <keyword>Grupo Español de Investigación del Cáncer de Mama - GEICAM/2014-02</keyword>
  <keyword>German Breast Group - GBG 81</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
